FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OND APP	ROVAL
OMB Noveles	2005 0007
OMB Number:	3235-0287
Estimated average b	urden

0.5

hours per response

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Belldegrun Arie				2. Issuer Name and Ticker or Trading Symbol Allogene Therapeutics, Inc. [ ALLO ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner							
(Last) 210 EAS	`	First)  AVENUE	(Middle)		3. Date of Earliest Transaction 03/13/2019				action (Month/Day/Year)					Officer below)	(give title	e Other (spe below)			
(Street) SOUTH FRANCI	(	ΣA	94080		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(	State)	(Zip)																
		Та	ble I - No	n-Dei	rivativ	ve Se	ecurities	s Ac	quired,	Dis	posed o	of, or Be	neficiall	y Owned					
Date		Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction D Code (Instr.		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common	Stock			03/	13/201	19			A		115,33	3 A	\$0.00	150,	333	]	D		
Common	Stock													3,710	,006			See footnote <sup>(1)</sup>	
Common	Stock													5,989	,352			See footnote <sup>(2)</sup>	
Common	Stock													1,691,781 I See foot		See footnote <sup>(3)</sup>			
Common	Stock													1 488 250 I I I I I		See footnote <sup>(4)</sup>			
			Table II -								osed of			Owned					
1. Title of Derivative Conversion or Exercise (Instr. 3)  2.			sansaction Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	un(s)			
Stock Option (Right to Buy)	\$26.89	03/13/2019			A		195,133		(5)	(	03/12/2029	Common Stock	195,133	\$0.00	195,1	.33	D		

## **Explanation of Responses:**

- 1. The securities are held in the name of the Belldegrun Family Trust.
- 2. The securities are held by VVAG Special Fund LLC (VVAG), of which VVAG LLC is the manager. The reporting person is a Senior Managing Director of VVAG LLC and may therefore be deemed to be the beneficial owner of the common shares held by VVAG. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- 3. The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- 4. The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- 5. 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter.

## Remarks:

/s/ Veer Bhavnagri, Attorney-in-03/15/2019 **Fact** 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\*\* Signature of Reporting Person

Date

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.